Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q3 FY21 Earnings Presentation
36 slides from Morepen Laboratories's earnings presentation, Feb 12, 2021
Slide 1: Morepen Laboratories - Investors Presentation Q3 FY21
MOREPEN Date: 12/02/2021 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investors Presentation (Q3’°F Y21) Feb
Slide 2: Morepen Laboratories Q3'FY21 Investor Presentation
Slide 3: Disclaimer/ Confidentiality
Disclaimer/ Confidentiality: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implie
Slide 4: Highlights for the Quarter
HIGHLIGHTS FOR THE QUARTER solidated) a asiry21 *120 % ‘212% Rs. 1.56 Q3'FY20 QM'FY20—
Slide 5: The Joy Of Growing Together
NOREEN The Joy Of Growing Together BULK DRUGS (API) Strong portfolio of lifestyle drugs including anti- diabetics, antihypertensives, neuropsychiatric, anti- cancers and anti-virals DIAGNOSTIC DEVICES Home diagnostics including glucose meters, BP monitors, nebulisers, weighing scales, digital and IR
Slide 6: "Reev
we "Reev e CF J gue 4 ‘: *EU-GM me * P* K JAAN
Slide 7: Baddi Facility (60 Acres)
Slide 8: Revenue Export and Domestic
Rs. in crores A 3a D5. % > oO ™ Oo 200 . “400 Export Domestic ie 0 64% Q3'FY20 Q3,FY21 Domestic FY'20 FY'21(9M) my 2a : Ma j . = MOREPEN: Q3'FY210" Q3'FY21 i TY Ps li, i
Slide 9: Segment Wise Revenue (Standalone)
SEGMENT WISE REVENUE ‘standatone) Formulations 12% Formulations 17.6% Diagnostic Devices 27% API 61% Domestic port 61% 39% Diagnostic Devices 21.6% 9M'FY 20-21 API Share 62% - 61% FY 19-20
Slide 10: Segment Wise Growth
SSCA WISE Too S Rs nore Diagnostic Devices API Business Q3'FY20 Q3'FY21 MOREPEN: Q3'FY21
Slide 11: API Division
Slide 12: API Growth
GY ae API GROWTH f ormance 9Mven — T rendsetting perf <q last fu Venue 400 ti | 200 150 100 2% A23% _ \ * 200 \ ke Beet 0 E >» a ' ' A Q3'FY20 Q3'FY21 oe = —_ — Export FY’18 FY'19 Pvp FY'21(9M) 67% ay MOREPEN ; 90 3'FY21 is ~
Slide 13: Export
o Rs. in crores Q3'FY21 EXPORT 9M'FY 21
Slide 14: Domestic
Go Rs. in crores 9M'FY 21
Slide 15: Widespread Global Base
WIDESPREAD GLOBAL BASE he | aVaiee Increasing Customer Reach 3 OZ¥: AfricSa m% >5 lex in y ll a 1,000 G0 abby: be a | > és Alley 4 : 7» ne Vo/ S. America 802 ; 11.5% 750 USA LEI Asia 500 ie ser Virng 41.1% Europe 250 10.8%°* FY'18 FY'19 FY'20 FY'21(9M) Increasing Customers Base FY'2(9M)
Slide 16: Countries Wise Break Up
Rs. in crores COUNTRIES WISE BREAK UP _ =a 9M'FY21 > Asia (Including India) Contributes 67% of Business ay - iW), Atal wt Gata. * . Js iy 2 eeniate F ee = ~~ Dy _ < Other (68) 4 20.4% ; f India — O 2 6 CAGR 29.9% 600 — } : \ 510.18 > 472.35 a 2% Sle Yamane 400 Israel rs} 6) 2.4% countries Thailand 2
Slide 17: Key API Products
KEY APIPRODUCTS GY eae Consistent Growth and Market Leadership Others 8.7% “sf Loratadine Rosuvastatin 9.9% Loratadine Montelukast 37.5% “he Atrovastatin 14.9% “fe Atorvastatin “fo Rosuvastatin Montelukast 29% MOREPEN: Q3°FY21
Slide 18: Intellectual Property: The Growth Engine
INTELLECTUAL PROPERTY The Growth Engine KDA Sod 129 120 Patents DMFs USA . Europe . Japan 10 30 China- IDLs New Products China . Taiwan . Australia FY'21 (9m): 5patent, 9dmf, 1IDL 5new products MOREPEN: Q3°FY21
Slide 19: Major Expansion Project
ll ae aT Nlel PROJECT ideas : ie, Major Expansio a4 ae ro) Wears ei im pF ggg wen ea Coa Ph es he ne 4 yo Ses tee + one Za pais i aoe iE : we Comet. Pa j ae Be ed ES Govt. folndia supporting API expansions plans and has also launched performance linked incentive scheme Cee ee KetionValue
Slide 20: Expanding API Market
EXPANDING API MARKET New Molecules add 15X market size 50 Market Size of the Product Basket _ \Piotal global market size of the all the products , ante the Company is presently sellingis only USD Billion $4.004 Bil and in. coming five years is goingto . 40 go down to s2}g35Mion since these are all o
Slide 21: Diagnostics Devices
Slide 22: Diagnostic Devices
MEDICAL coats Rs. in crores DIAGNOSTIC DEVICES F)i) Q3'FY21 Ny Manufactured inIndia ‘10 4 % Q3'FY20 Q3'FY21
Slide 23: Key Products Q3'FY21
KEY PRODUCTS Q3'FY21 emne ec is ‘210% Gluco Meters BP Meters aol 22% Thermometers Nebulisers MOREPEN: Q3'FY21
Slide 24: 62% Glucometer Share of Gross Revenue
Slide 25: New Meters Installed
# % | — | anne, 4 ; -§5smilliontest Tee: New Meters Installed ._ = on . ‘ / J a Rel ===) Eis Cen aes are
Slide 26: Finished Dosages
a | . FINISHED DOSAGES
Slide 27: Formulation
FORMULATION Rs. in crores & Q3'FY21 Branded & Generics A3% Q3'FY20 Q3'FY21 Affected by Covid-19 Q-o0-Q recovery coming
Slide 28: e ne See
{Gj 15 softgels Gj 15 Tablets e 116 Tbs Rana \ Sultamicillin 750mg Tablets SALTUM-DS acen- Stet o ak a Paya) e neSee mL Multivitamin Weta Bring Back The Missing &Mutiminera R 80:90 mM. Happiness in Life with DHA, Cefpodoxime Multivitamin & Multimineral & Potassium with DI Clavulanate for Oral Suspen
Slide 29: Dr. Morepen
Slide 30: Dr. Morepen
S Rs. in crores DR. MOREPEN Q3'FY21 Health in your hands MMG Q3'FY20 =
Slide 31: Dr. Morepen
DR. MOREPEN 109 = “Aminacrine HCL, Cetrimide Cream 7 Burnol (ZA)
Slide 32: =a Pitti ae
ail orc Yoo B Steers cme -
Slide 33: Financial Highlights (Consolidated) Q3'FY21
Rs. in crores FINANCIAL HIGHLIGHTS (consolidated) Q3'FY21 Exponential Growth 400 “32% 25 120% 20 a 300 15 200 ee 10.83 400 5 0 0 ; ; Q3'FY21 Q3'FY20 Q3'FY20 Q3FY21 Net Revenue Profit before tax on A 29%0 A 64%0 5120% A212% 40 2 30 200 1.5 20 1 100 10 0.5 Oo, 0 0 Q3'FY20 Q3'FY21 Q3'FY20 Q3'FY21 Q3'FY
Slide 34: Operating Ratios (Consolidated)
Rs. in crores OPERATING RATIOS consolidated) Q3'FY'21 Excellent Performance Indicators -10 % *10 % 15% 24% 10% 10.5% OW 5% 0% MAR'20 DEC'20 FY20 9M'FY21 FY'20 9M'FY21 EBIDTA “age Debtors (Month's Sale) Inventory Turnover (Months) 13% ‘92% ‘66% "15 Yo 8% 6% ai 4% Cy 2% 0% FY'20 QM'FY21 FY'20 QM'FY21
Slide 35: Balance Sheet Ratios
Rs. in crores BALANCE SHEET RATIOS (Standalone) 9M'FY'21 Growth from within 14% 32% 125 600 100 300 119.65 119.65 Px tm) 100 75 ee BEE 400 200 4) 15 50 50 200 100 25 25 0 0 MAR'20 DEC'20 MAR'20 DEC'20 MAR'20 DEC'20 MAR'20 DEC'20 Preference Capital Total Capital Employed Equity Capital Reserve & Surp
Slide 36: Thank you